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The three major mitogen-activated protein kinases (MAPKs) p38, JNK, and ERK are signal transducers involved in a broad range
of cell functions including survival, apoptosis, and cell diﬀerentiation. Whereas JNK and p38 have been generally linked to cell
death and tumor suppression, ERK plays a prominent role in cell survival and tumor promotion, in response to a broad range
of stimuli such as cytokines, growth factors, ultraviolet radiation, hypoxia, or pharmacological compounds. However, there is a
growing body of evidence supporting that JNK and p38 also contribute to the development of a number of malignances. In this
paper we focus on the involvement of the MAPK pathways in prostate cancer, including the less-known ERK5 pathway, as pro- or
antitumor mediators, through their eﬀects on apoptosis, survival, metastatic potential, and androgen-independent growth.
1.Introduction
Mitogen-activated protein kinases (MAPKs) are serine/thre-
onine kinases that mediate intracellular signaling associated
withavarietyofcellularactivitiesincludingcellproliferation,
diﬀerentiation, survival, death, and transformation [1, 2].
The three main members that integrate the MAPK family
in mammalian cells are stress-activated protein kinase c-
Jun NH2-terminal kinase (JNK), stress-activated protein
kinase 2 (SAPK2, p38), and the extracellular signal-regulated
protein kinases (ERK1/2, p44/p42) (Figure 1). In addition,
other less-characterized MAPK pathways exist, such as
the extracellular regulated kinase 5 (ERK5) pathway [3,
4]( Figure 1). Albeit with multiple exceptions, JNK and
ERK5 are generally associated with apoptosis induction,
while ERK1/2 are generally associated to mitogenesis, and
inversely related to apoptosis [3, 4], and contradictory eﬀects
on cell death have been described to p38 [5–12].
In mammalian cells, ERK, p38, and JNK activities
are, respectively, regulated by diﬀerent MAPKs cascades,
which provide a link between transmembrane signaling and
changes in transcription and that are activated in response
to diﬀerent environmental or developmental signals [4]
(Figure 1). Depending on the cell type, a particular MAPK
cascade may be involved in diﬀerent cellular responses. The
JNK and p38 signaling pathways are activated by proinﬂam-
matory (TNFα, IL-6 or IL-1) or anti-inﬂammatory (EGF,
TGF-β) cytokines, but also in response to cellular stresses
such as genotoxic, osmotic, hypoxic, or oxidative stress. The
JNK pathway consists of JNK, an MAPKK such as SEK1 (also
known as MEK4) or MEK7, and an MAPKKK such as ASK1,
MEKK1, mixed-lineage kinase (MLK), or transforming
growth factor-β-activated kinase 1 (TAK1) [13, 14]. In the
p38 signaling pathway, distinct MAPKKs such as MEK3
and MEK6 activate p38, and these can be activated by the
same MAPKKKs (such as ASK1 and TAK1) that function
in the JNK pathway. In the ERK signaling pathway, ERK1
or ERK2 (ERK1/2) is activated by MEK1/2, which in turn
is activated by a Raf isoform such as A-Raf, B-Raf, or Raf-
1 (also known as C-Raf) and also by TRAF-2 and TRAF-6.
The kinase Raf-1 is activated by the small Ras-like GTPase,
whose activation is mediated by the receptor tyrosine kinase
(RTK)-Grb2-SOS signaling axis [15]. Members of the Ras
family of proteins, including K-Ras, H-Ras, and N-Ras, play
a key role in transmission of extracellular signals into cells
[16]( Figure 1).
The aim of this paper was to focus on the possible
involvement of MAPKs in several transduction pathways2 Journal of Signal Transduction
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Figure 1: Mitogen-activated protein kinase (MAPK) signaling. MAP kinases are activated by upstream kinases such as MAP kinase kinase
(MAPKK), that include MEKs 1, 2, 3, 4, 5, 6, and 7. In turn, MAPKKs are activated by several diﬀerent MAP kinase kinase kinases
(MAPKKKs).Numerousstimulatoryfactorssuchascytokines,mitogens,ordeathreceptorscanactivateMAPKKKs.EachMAPK,depending
on the stimulus and cell type, can phosphorylate diﬀerent transcription factors.
related with prostate cancer development as well as the
possible functional role of MAPKs in cell death/survival/
proliferation decisions depending on the cell type, stage, and
cell stimulus. We also discuss the possible value of members
of these pathways as potential therapeutic targets.
2. Jun N-Terminal Kinase (JNK)
JNK proteins, also called stress-activated protein kinases
(SAPKs), share a threonine-proline-tyrosine (TPY) motif
within their activation loop [17]. They have been involved
in development, morphogenesis, and cell diﬀerentiation
[17]. The earliest discoveries included the identiﬁcation of
the three mammalian JNK genes, namely, JNK1, JNK2,
and JNK3 (SAPK-γ,S A P K - α,a n dS A P K - β,r e s p . )w h i c h
can generate 10 isoforms by alternative splicing [18, 19].
Alternative splicing further increases the diversity of JNK
proteins; however apart from early biochemical studies on
these splice forms [16] their functional signiﬁcance in vivo
remains largely unexplored [19]. The products of JNK1 and
JNK2 are ubiquitously expressed in almost all cell types and
tissues, whereas JNK3 is localized primarily in brain, heart,
and testis. Due to their diﬀerential expression distribution
it is thought that JNK3 presents diﬀerent functions than
JNK1 and JNK2, whereas these latter may have redundant
functions [20]. Investigations on JNKs have focused on
their activation in response to diverse extracellular stimuli
including ultraviolet (UV) and gamma radiation, inﬂam-
matory cytokines (IL-6, IL-1, and TNF), and cytotoxic
drugs (Figure 2)[ 21, 22] .T h e s es t i m u l ia r ea b l et oa c t i v a t e
JNK through multiple and even overlapping cascades in
which participate members of the small Ras-like GTPases
or several MAPKKKs (Figure 1). For its complete activation
JNKrequiresdualphosphorylationofthreonineandtyrosine
residues. MEK4 and MEK7 preferentially phosphorylate at
tyrosine and threonine, respectively [23–27], being both
MAPKKs needed to fully activate JNK [4, 28]. Depending
on the stimulus and cell type, JNKs phosphorylate diﬀerent
substrates,includingtranscriptionfactors(AP-1,ATF-2,Elk-
1, c-Myc, p53, MLK2) and several members of the Bcl-2
family, among others [17, 20, 29]( Figure 1).
Several authors suggest that JNK activity is chronically
altered in various cancer types such as those of the prostate
[30, 31], breast [32, 33], pancreas, or lung [34, 35]. Both
JNK1 and 2 have been shown to exert pro- as well as
antitumor actions in a number of in vivo and in vitro models
of malignancies [6, 36]. A number of ﬁndings suggest that
in apoptosis JNKs have opposite functions depending on the
cellular stimulus and type or even the JNK isoform.Journal of Signal Transduction 3
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Figure 2: JNK and p38 MAPKs mediate apoptotic cell death
induced by a variety of compounds in prostate cancer cells.
Studies into the status of JNK in human prostate tissues
are scarce. Both nuclear and total JNK expression seems
to be augmented in human malignant prostate epithelium
in comparison with normal or benign hyperplasic (BPH)
epithelium [30–40]. We are not aware of studies that analyze
theactivationstateofJNKinorgan-conﬁnedhumanprostate
cancers. Nevertheless in human metastatic lesions, and late-
stage carcinomas and metastatic deposits from a murine
model of prostate cancer, JNK phosphorylated forms seem
to be reduced [39, 41, 42].
In spite of its prominent role as a proapoptotic factor,
as in other malignances, both pro- and antitumor actions
have been attributed to JNK in prostate cancer. Hence, a
great number of agents have been shown to trigger apop-
tosis through JNK. These include gamma-tocotrienol [43],
dicoumarol [44], benzimidazole derivatives [45], alpha-
chaconine, gallic acid [34], ursolic acid [35], melatonin [36],
and isothiocyanates [46, 47]( Figure 2). It is of interest to
note that androgen deprivation, the most common therapy
used as treatment for advanced prostate cancer, may elicit
apoptosis through JNK activation [48]. In the context of its
proapoptotic role JNK has been linked to reactive oxygen
species(ROS).Someworkshavehighlightedthecapabilityof
JNKtotriggerapoptosisthroughROSproductioninprostate
cancer cells [49, 50]. Conversely, ROS may induce apoptosis
acting through JNK activation. For instance, both genipin-
and guggulsterone-induced prostate cancer cell apoptoses
are caused by ROS-dependent JNK activation [51, 52].
Regarding to its antiapoptotic function, JNKs have been
involved in protection from serum starvation-, Fas-, and (at
early phase) glucose deprivation-induced apoptosis [53–55].
Besides promoting prostate cancer development by pro-
tecting cells from apoptosis, JNK may be involved in prostate
cancer metastasis, through its ability to regulate cell adhe-
sion, invasion, and migration. Thus, JNK has been shown
to promote the expression of some proteins responsible for
extracellular matrix degradation during invasion in prostate
cancer cells, such as matrix metalloproteinases (MMPs)-2
and -9, and urokinase-type plasminogen activator (u-PA)
[56–58]. Moreover, Kwon et al. [56] reported that chemical
inhibition of JNK in DU145 prostate cancer cells reduces
both cell migration and vascular-endothelial growth factor
(VEGF)expression,aproangiogenicfactorthatmayfacilitate
tumor growth and metastasis.
3.Stress-ActivatedProteinKinase2 (p38)
p38 family members contain a TGY (threonine-glycine-
tyrosine) motif in their activation loop. These kinases play
roles in cell diﬀerentiation, growth, proliferation, survival,
and apoptosis [59–61]. Four isoforms of p38 exist, namely,
p38α, β, γ,a n dδ, which exhibit some diﬀerent func-
tional properties. Whereas p38α and p38β are ubiquitously
expressed, p38γ and p38δ expression is restricted to some
tissues such as muscle, testis, pancreas, lung, kidney, or
endocrineglands[62–64].p38isactivatedincellsinresponse
to stress signals, proinﬂammatory (TNFα,I L - 6o rI L - 1 )o r
anti-inﬂammatory (EGF, TGF-β) cytokines, UV radiation,
and heat and osmotic shock [59, 65]. A great number of
MAPKKs and MAPKKKs (e.g., Mlk1-3, MEKK1-4, TAK,
ASK1/2) upstream of p38 have been identiﬁed. Both MAP-
KKs and MAPKKKs are generally activated by small Ras-like
GTPases as Rac1, Cdc42, RhoA, and RhoB [64]. Activated
p38 phosphorylates and regulates many transcription factors
(including ATF-2, NF-κB, Elk-1, Max, MEF-2, Mac, p53, or
Stat1) [65–67] and other cell cycle and apoptotic mediators
(e.g., Cdc25A, Bcl-2) [61]. p38 has been shown to enhance
cell survival in response to stress stimuli, for instance, in
response to DNA damage [61–68]. Triggering of pro- or
antiapoptotic p38-mediated response seems to depend on
the stimulus, the cell system, and the p38 isoform involved
[64].
Several studies suggest that p38 play an important role
in leukemia [64], lymphomas [69], and a number of solid
m a l i g n a n c e ss u c ha sb r e a s t[ 65], prostate [70], gastric [71],
or lung [72]c a n c e r s .
Both p38 and its active form p-p38, as well as some
upstream kinases (PAK1, MEK6, MEK4), are overexpressed
in human cancerous prostatic epithelium [11, 30, 41]. This
agrees with the enhanced levels of the phosphorylated form
of the well-established p38 substrates Elk-1 and ATF-2 at the
same compartment [11]. Uzgare et al. [41], using a trans-
genic mouse model for prostate cancer, described that p-p38
is overexpressed in prostatic intraepithelial neoplasia (PIN),
well-diﬀerentiated and moderately diﬀerentiated cancers
while was reduced or absent in late-stage adenocarcinomas
and metastatic deposits. However, like in other tissues,
studies focused on p38 function in the prostate malignancy
reveal that this MAPK can elicit multiple and even opposite
responses, which seem to vary depending on the cell system
and context.
A proapoptotic role for p38 has been established in a
number of prostate cancer in vitro models and conditions.
p38 promotes apoptosis induced by 2-methoxyestradiol [5],
melatonin[6],proanthocyanidins[7],raloxifene[8],carpro-
fen [9], or protoapigenone [10]( Figure 2). By contrast, p38
exertsaprotectiveeﬀectinTNF-inducedapoptosisinLNCaP
cells, which represents a good model of well-diﬀerentiated
tumor [11].4 Journal of Signal Transduction
In spite of having a prominent proapoptotic role p38
may contribute to prostate cancer progression by promoting
tumor growth, androgen independence acquisition, and
metastasis. It has been proposed that IL-6 may support
androgen-independent tumor growth by enhancing andro-
gen receptor (AR) expression/activity. Lin et al. [73]d e m o n -
strated that, in turn, the IL-6-induced androgen response
depends on p38 activity. p38 seems to play a critical role
in hypoxia-reoxygenation-induced increase in AR activity, as
well as increased survival, clonogenicity, and invasiveness in
prostate cancer cells [74], thus providing additional support
for a role for p38 in androgen dependence acquisition.
Huang et al. [75] showed in PC3 cells that p38 MAPK is
necessary for TGF-β-mediated activation of MMP-2 and
cell invasion in prostate cancer. Moreover, p38 has been
involved in the invasion and migration abilities of the
prostate cancer DU145 cells, by enhancing the expression of
MMPs-2 and -9, and urokinase-type plasminogen activator
(u-PA) [76]. Xu et al. [77] also described MEK4 as a
regulator and activator of MMP-2. In agreement, Tang and
Lu [78] found that p38 activity contributes to adiponectin-
induced integrin expression and migration capability of
human prostate cancer cells. Therefore, and in spite of
displaying proapoptotic functions, p38 may constitute a
target for prostate cancer treatment given its demonstrated
contribution to some prostate cancer hallmarks, as androgen
dependence and metastatic phenotype acquisition.
4.ExtracellularSignal-RegulatedProtein
Kinases (ERK1/2)
ERK has a threonine-glutamic acid-tyrosine (Thr-Glu-Tyr)
motif [79, 80] that plays a central role in stimulation of
cell proliferation [81, 82]. The biological consequences of
phosphorylation of ERK substrates include increased pro-
liferation, diﬀerentiation, survival [83], angiogenesis [84],
motility [85], and invasiveness [86]. The two isoforms of
ERK, referred to as ERK1 (or p44) and ERK2 (or p42), share
85% amino acid identity and represent a convergence point
for mitogenic signaling from a diverse array of pathways
[87–89]. Both are ubiquitously expressed, although their
relative abundance in tissues is variable. For example, in
many immune cells ERK2 is the predominant species, while
in several cells of neuroendocrine origin they may be equally
expressed [90].
The ERK pathway is triggered mainly by mitogens
and cytokines (Figure 1), acting through receptor tyro-
sine kinases, G-protein-coupled receptors, and nonnuclear
activated steroid hormone receptors [4, 65]. Most of the
signals activating the ERK pathway are initiated through
receptor-mediated activation of Ras [4] by stimulating the
exchange of GDP bound to Ras for GTP [91]. Then, Ras
phosphorylates Raf-1. Then, a MAPK cascade is initiated
in which Raf-1 sequentially phosphorylates MEK1/2 and
ERK1/2.Later,ERK1/2translocatetothenucleusinaprocess
that culminates in modulation of gene transcription through
the activation of several transcription factors such as Ets-
1[ 4], ATF-2, c-Fos, c-Myc, Elk-1 [92], or NF-κB[ 29]
(Figure 1). At the same time, ERK1/2 can also phosphorylate
cytoplasmic and nuclear kinases, such as MNK1, MNK2,
MPKAP-2, RSK, or MSK1 [90].
TGF-β and EGF are growth factors that can induce
tumor progression by means of the ERK pathway [93–96].
Several studies showed that these factors are overexpressed
in prostate cancer in comparison with normal tissue [95–
98]. In diﬀerent tumor cells, expression of some EGF
family members such as EGF or TGF-α is associated with
poor patient prognosis or resistance to chemotherapeutics
[94–99]. IGF-1 and EGF stimulate intracellular signaling
pathways converging at the level of ERK2 [100], which is a
keykinasemediatorofgrowth-factor-inducedmitogenesisin
prostate cancer cells [101]. The two major substrates of the
IGF-1 receptor, insulin receptor substrate-1 [102]a n dS h c ,
are known to contribute to IGF-1-induced activation of ERK
[103].
The ERK signaling pathway plays a role in several steps
of tumor development [14]. In fact, some components of
the Raf-MEK-ERK pathway are activated in solid tumors
(such as prostate or breast cancer) and hematological
malignances [104–106]. In approximately 30% of human
breast cancers, mutations are found in the ERK1/2 MAPK
pathway [65]. ERK1/2 and downstream ERK1/2 targets are
hyperphosphorylated in a large subset of mammary tumors
[107].MutationsofK-Rasappearfrequentlyinmanycancers
including those of the lung and colon [108]. Mutations
in the B-Raf gene are responsible for 66% of malignant
melanomas [109]. Increased expressions of Raf pathway has
been associated with advanced prostate cancer, hormonal
independence, metastasis, and a poor prognosis [110].
Moreover, prostate cancer cell lines isolated from patients
with advanced cancer (LNCaP, PC3, DU145) expressed low
levels of active Raf kinase inhibitors [105]. TNF-α acts as
an ERK activator in some cases related to inﬂammation and
cell proliferation. In this way, Ricote et al. [11] showed that
ERK phosphorylation was notably increased by TNF-α in a
dose-dependent manner in LNCaP cells. In prostate cancer,
presence of Raf-1 and MEK1 in conjunction with elevated
ERK1 and ERK2, and their phosphorylated forms, suggests
that stimulation of cell proliferation could be triggered by
IL-6 via the ERK pathway [104]. In fact, IL-6 expression
increased in prostate cancer in comparison with normal
tissue [104, 111]. Moreover, LNCaP cells which produce IL-
6 show increased proliferation, at least in part, due to ERK
activation [112]. Recently, a phase I clinical trial has revealed
the ability of an anti-IL-6 antibody (siltuximab) to inhibit
ERK1/2 phosphorylation in prostate tumors [113].
Severalinvestigatorssuggestassociationsbetweendecline
in ERK activity and advanced malignancy [114, 115].
Conversely Gioeli et al. [116] demonstrated that ERK
activation is correlated with tumor malignancy. Junttila et
al. [4] demonstrated in the TRAMP mouse model that
ERK activation is linked to prostatic epithelial proliferation
and initiation of prostate cancer development, while ERK
inactivation is correlated with the emergence of a poorly
diﬀerentiated metastatic and androgen-independent pheno-
type. Activated ERK mediates activation of the androgen
receptor and/or PSA secretion through the growth factorJournal of Signal Transduction 5
receptor tyrosine kinase, Her2/Neu (also known as erbB2)
in androgen-independent prostate cancer cells [117]. Other
important issue of this pathway in tumor development is
that the phosphorylation by ERK of proteins such as myosin,
calpain, focal adhesion kinase, and paxillin promotes cancer
cell migration. Also, ERK can promote the degradation of
extracellular matrix proteins and consequent tumor invasion
[14].
ERK may also induce the phosphorylation of apoptotic
regulatory molecules including bcl-2 family members (e.g.,
Bad, Bim, and controversially Bcl-2) and caspase 9 [93].
There are pieces of evidence suggesting a protective eﬀect
in cells by NF-κB activation via ERK [118, 119]. Upon cell
stimulation NF-κB is translocated into the nucleus [120],
where it promotes the expression of several antiapoptotic
genes such as inhibitors of apoptosis proteins (IAPs) [121]
and bcl-2 family members [122].
5. ERK5
ThefourthMAPKofinterestinthispaperisERK5.ERK5isa
large molecular size kinase [123] identiﬁed independently by
two groups. One used a two-hybrid screen with an upstream
activator MEK5 as the bait; the other used a degenerate PCR
strategy to clone novel MAPK [123, 124]. ERK5 is activated
by growth factors [125], integrin engagement [126], and
cell stress [111] and contributes to expression induction of
Ap1 (cJun [127]a n dF o s[ 128]), MEF family group (e.g.,
MEF2C, a well-characterized target [129], and c-Myc [130]
transcription factors).
In an in vitro study on androgen-independent PC3
cells, McCracken et al. [131] described ERK5 overexpresion
related to proliferative, migrative, and invasive capabilities,
establishing the potential importance of ERK5 in aggressive
prostate cancer. In other study, Sawhney et al. [126] hypoth-
esized that ERK5 activation could promote cancer metastasis
through its ability to regulate cell adhesion and motility.
6.New Perspectives
The literature reviewed in this paper suggests that the
MAPKtransductionpathwaysareinvolvedinprostatecancer
development. The ability of JNK, p38, and ERK to act
either as prostate cancer suppressors or promoters depends
on the cell type, developmental stage, and speciﬁc stimuli.
Nevertheless, the molecular roles of these proteins are not
known at all. The aim of future studies might be directed
towards revealing the factors and mechanisms that account
for the diﬀerential function of JNK, p38, and ERK MAPKs
as pro- or antitumor factors. It may lead to the development
of therapeutic approaches to eﬀectively target the protumor
eﬀects of the MAPK pathways.
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